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Abstract
Background: A cross-talk between different receptor tyrosine kinases (RTKs) plays an important role in the
pathogenesis of human cancers.
Methods: Both NIH-Met5 and T24-Met3 cell lines harboring an inducible human c-Met gene were established. C-
Met-related RTKs were screened by RTK microarray analysis. The cross-talk of RTKs was demonstrated by Western
blotting and confirmed by small interfering RNA (siRNA) silencing, followed by elucidation of the underlying
mechanism. The impact of this cross-talk on biological function was demonstrated by Trans-well migration assay.
Finally, the potential clinical importance was examined in a cohort of 65 cases of locally advanced and metastatic
bladder cancer patients.
Results: A positive association of Axl or platelet-derived growth factor receptor-alpha (PDGFR-a) with c-Met
expression was demonstrated at translational level, and confirmed by specific siRNA knock-down. The
transactivation of c-Met on Axl or PDGFR-a in vitro was through a ras- and Src-independent activation of mitogen-
activated protein kinase/extracellular signal-regulated kinase (MEK/ERK) pathway. In human bladder cancer, co-
expression of these RTKs was associated with poor patient survival (p < 0.05), and overexpression of c-Met/Axl/
PDGFR-a or c-Met alone showed the most significant correlation with poor survival (p < 0.01).
Conclusions: In addition to c-Met, the cross-talk with Axl and/or PDGFR-a also contributes to the progression of
human bladder cancer. Evaluation of Axl and PDGFR-a expression status may identify a subset of c-Met-positive
bladder cancer patients who may require co-targeting therapy.
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Background
The RTK c-Met is expressed during normal develop-
ment and plays a crucial role in many cell regulatory
processes [1]. After binding to its cognate ligand-hepa-
tocyte growth factor (HGF), activated c-Met transmits
signals implicated in the cell proliferation, motility, sur-
vival, and morphogenesis [2-4]. C-Met is over-expressed
and usually associated with metastatic progression of a
variety of human malignant tumors, including bladder
cancer [1,5]. We have reported that c-Met is over-
expressed in 32.3%, 63.2%, and 65.2% of superficial,
locally advanced and metastatic bladder cancer, respec-
tively [6]. Over-expression of c-Met is positively asso-
ciated with muscle invasion and poor long term survival
(p < 0.001), while it is not related to patient outcome in
the subset of superficial bladder cancer. Miyata et al.
also reported the significance of c-Met in bladder cancer
development and as an important predictor of metasta-
sis and patient survival [7]. Therefore, c-Met is emerging
as a novel therapeutic target in many solid tumors
[8-10].
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[11]. In addition to heterodimeric complex formation of
the same subfamily [6,11-14], heterologous RTK interac-
tion is also involved in the pathogenesis of human can-
cers, e.g. between EGFR and RON (a member of the c-
Met family) [15,16]. The biological significance of inhibi-
tion of both RTK signaling pathways of cancer cells was
demonstrated in the context of cell proliferation, migra-
tion, anti-apoptosis and transformation in vitro.[ 1 5 ] .
Therefore, identification of cross-talk partners of c-Met
involved in the tumorigenesis may provide important
biomarkers for co-targeting therapy. In our prior RTK
profiling experiment, c-Met was frequently co-expressed
with Axl, platelet-derived growth factor receptor a
(PDGFR-a), DDR2 and/or IGF1R in the same uroepithe-
lial cells [17], suggesting the existence of yet unspecified
cross-talk partners of c-Met.
Axl overexpression is detected in various human can-
cers, and is associated with invasiveness and/or metasta-
sis of carcinoma of the breast [18], stomach [19], kidney
[20], lung [21], and prostate [22]. High expression of
PDGFR-a is also detected in a variety of tumors, such
as prostatic intraepithelial neoplasia, and carcinoma of
the ovary, kidney, breast and liver [23-26]. Furthermore,
PDGFR-a expression provides additional predictive
value related to breast cancer progression [23], and
patient’s survival in the kidney cancer [27] or lung can-
cer [28]. The implications of these two receptor-related
signaling events in the bladder carcinogenesis, however,
remain unclear. This study was aimed to identify the
novel interaction partners of c-Met, investigate their
regulation, effect on biological activity, and the potential
significance in association with patient outcome.
Methods
Cell Lines, transfection, and stable cell line establishment
NIH/3T3 mouse fibroblast cell line and bladder cancer cell
line T24 were obtained commercially. The four bladder
cancer cell lines UB09: stage B2; UB40: stage A, papillary;
UB47: stage B1; TSGH8301: stage A were established
from patients of transitional cell carcinoma of the urinary
tract [6,29]. UB47 was cultured in RPMI medium 1640
supplemented with 15% fetal bovine serum (FBS). Other
cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS.
The plasmids pTRE-Met and pTet-Lac-Hyg were
transfected into NIH/3T3 and T24 cells by Lipofecta-
mine™ 2000 reagent according to manufacturer’s proto-
col (Invitrogen, Carlsbad, CA, USA) [30]. Two stable
cell lines: NIH-Met5 and T24-Met3 were established.
Microarray array
RNA was isolated using TRIzol reagent (GIBCO BRL,
Gaithersburg, MD, USA), followed by mRNA purification
using Oligotex™ mRNA kit (Qiagen, Valencia, CA, USA).
RNA samples were reverse transcribed into cDNA fluores-
cently labeled either with Cy3 or with Cy5. The labeled
cDNA was hybridized with a microarray cDNA chip con-
taining 192 RTK genes [31]. Data were imported and nor-
malized using MeV: MultiExperiment Viewer (Dana-
Farber Cancer Institute, http://www.tm4.org/mev.html)
[32]. Clustering affinity search technique (CAST) was used
for gene expression cluster analysis. There are 23 clusters
after CAST analysis [33], the gene expression profiles of 8
genes showing the best correlation with c-Met gene were
clustered as one group (table 1).
Antibodies
Anti-phospho-tyrosine antibody was purchased from BD
Transduction Laboratories (Lexington, KY, USA), and
antibodies to Axl, c-Met, p-Met (phosphorylation of c-
Met;Tyr 1234), PDGFR-a,a n dp - P D G F R - a (phosphory-
lation of PDGFR-a;Tyr 754) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). The Ras
antibody was obtained from Calbiochem (Merck, Darm-
stadt, Germany), Sp1 from Upstate Biotechnology Inc.
(Golden, CO, USA), p-Axl (phosphorylation of Axl;Tyr
702) from Cell Signaling Technology Inc. (Beverly, MA,
USA) and b-actin was purchased from Sigma-Aldrich
(St. Louis, MO, USA). The Src antibody was obtained
from Millipore (Billerica, MA, USA) and p-Src (phos-
phorylation of Src;Tyr 418) purchased from Invitrogen
(Carlsbad, CA, USA).
Western blot analysis
The western blot analysis was performed as previously
described [6]. Briefly, the total lysates were prepared
using RIPA solution. Total protein (50 μg) was analyzed
by polyacrylamide gel electrophoresis and transferred to
the PVDF membrane. The membrane was probed with
targeted protein antibodies and the immune complex
was detected with an enhanced chemiluminescence
Table 1 The mRNA expression levels of eight RTK genes
clustered together with c-Met in RTK c-DNA microarray
analysis
RTK
name
NIH/
3T3
NIH-Met5 day
1
NIH-Met5 day
4
NIH-Met5 day
7
Axl -0.43 1.48 -0.71 -0.34
ERBB2 -0.24 1.34 -1.07 -0.02
ERBB3 -0.34 1.47 -0.79 -0.35
Met 0.02 1.18 -1.26 0.06
MST1R -0.35 1.45 -0.84 -0.26
PDGFRa -0.40 1.48 -0.70 -0.38
PDGFRb -0.20 1.13 -1.25 0.32
TIE1 -0.24 1.47 -0.76 -0.47
TIE2 -0.01 1.38 -0.97 -0.40
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USA).
siRNA transfection
Specific siRNA sense sequences were as follows: c-Met
siRNA: 5`-AAGTGCAGTATCCTCTGACAG-3`, Axl
siRNA: 5`-CGTGGAGAACAGCGAGATTTA-3`, and
PDGFRa siRNA: 5`-CGAGACGATTGATGCAG-
GATA-3`. The cells (5 × 10
5) were seeded into a 6-cm
cell culture dish and incubated in DMEM medium with-
out antibiotics. Lipofectamine 2000 reagent (10 μl) was
diluted in 500 μl of DMEM serum-free media and incu-
bated for 5 min at RT. The siRNA was diluted in 500 μl
of DMEM serum-free medium to the assigned concen-
trations. Mock transfection was conducted in parallel
using distilled water as the negative control. Then cells
w e r ei n c u b a t e da t3 7 ° Ci nt h e5 %C O 2 incubator for 4
h. The media were replaced with normal media and
cells were incubated for additional 48 h before protein
extraction.
Trans-well migration assay
The effect of RTK cross-talk on cell migration was ana-
lyzed in TSGH8301 bladder cancer cells using a 24-well
Transwell™ system (Corning inc., Lowell, MA). Briefly,
cells were cultured in a 6-cm plate and transfected with
c-Met, Axl, or PDGFR-a siRNA for 24 h, respectively.
Then, cells were resuspended with serum-free medium
and added into the upper chamber of the trans-well
insert (2 × 10
5 cells/well). The 10% FBS-containing
DMEM was added in the lower chamber. Cells were
incubated h at 37°C for 36 h. Migrated cells were fixed
with 4% formaldehyde in PBS and stained with 2% crys-
tal violet in 2% ethanol. The non-migrated cells in the
upper chamber were removed by wiping with a cotton
swab. The cells on the lower surface of the filter, repre-
senting migration of the cells through the membrane,
were counted under a light microscope.
Clinicopathological characteristics of study cases
Since c-Met is important in the progression of bladder
cancer, both locally advanced and metastatic bladder
tumors were recruited to evaluate the significance of co-
expression patterns of c-Met and other RTKs. Archival
material of 65 patients (44 men and 21 women; age
range, 40 to 84 yr old; mean ± SD, 61.5 ± 9.4 yrs) with
locally advanced or metastatic urothelial bladder cancer
(21pT2, 27pT3, 17pT4) was analyzed for RTK expres-
sion. These patients were diagnosed and treated in the
National Cheng Kung University Hospital, Tainan, Tai-
wan, between 1990 and 1999 years. The numbers with
low or high grade urothelial carcinoma were 20 and 45,
respectively, according to definitions described pre-
viously [34]. Seven patients received partial cystectomy
and remaining fifty-eight patients received radical
cystectomy and bilateral pelvic lymph node dissection.
Among them, 23 (35.4%) patients had pelvic lymph
node involvement. An adjuvant systemic chemotherapy,
including methotrexate, vinblastine, epirubicin, and cis-
platin (M-VEC regimen), was given to 20 patients
(30.8%) after radical cystectomy. The survival status was
determined by outpatient clinic records and/or con-
firmed by interview with patients’ families. Clinical fol-
low-up ranged from 26 to 140 months (mean ± SD:
50.02 ± 6.46 months). The time of the first tumor recur-
rence and for disease specific survivals were counted.
The time is calculated until the death of the patient due
to bladder cancer. Patients who died of other causes or
were still alive at the last follow-up were censored.
Immunohistochemical staining
Immunostaining procedures were described in detail
previously [6]. Briefly, tissue sections were incubated at
RT for 2 h with monoclonal anti-cMet (1:100 dilution;
Santa Cruz), anti-AXL (1:10 dilution; Santa Cruz) and
anti-PDGFR-a (1:200 dilution; Santa Cruz) antibodies
raised against the membrane protein. The optimal dilu-
tion was determined by using human kidney as a posi-
tive control [5]. Then StrAviGen Super Sensitive
MultiLink kit (BioGenex Laboratories, Inc., San Ramon,
California) was used to detect the resulting immune
complex. Peroxidase activity was visualized using an
aminoethyl carbazole substrate kit (Zymed Laboratories,
Inc., San Francisco, Califonia).
Because no apparent difference of staining intensity
was detected, only the proportion of tumor cells stained
for c-Met, Axl or PDGFR-a was considered in classifica-
tion [6]. “High level of expression” indicates > 50% of
the tumor cells were immunostained, “low level of
expression” indicates 10%-50% reactivity; and “negative”
indicates < 10% staining for RTK protein.
Statistical analysis
The association between tumor staging or gross charac-
teristics with expression status of c-Met, Axl, and
PDGFR-a was analyzed by Chi-square test as appropri-
ate. The correlation between co-expression patterns of
RTKs and disease-specific survival of cancer patients
was constructed according to Kaplan-Meier method by
Log rank test.
Results
Establishment of stable cell lines harboring inducible c-
Met gene
Two stable cell lines, designated as NIH-Met5 (mouse
fibroblast) and T24-Met3 (human bladder cancer cell),
were established to harbor the inducible c-Met gene,
which was expressed only in the absence of tetracycline
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c-Met was over-expressed, the increase of its phosphory-
lated form (p-Met) indicates an auto-phosphorylation
(Figure 1A, lane 3; Additional file 1, lane 6). Expression
of p-Met was further enhanced 10 min after treatment
with hepatocyte growth factor (HGF; Sigma, St. Louis,
MO, USA) (Figure 1A, lane 4; Additional file 1, lane 7).
In contrast, parental NIH/3T3 cells did not express c-
Met and p-Met (Figure 1A, lanes 1 and 2; Additional
file 1, lane4 1-4). It is interesting to note that c-Met or
p-Met was not expressed in NIH-Met5 cells when trea-
ted with Tet alone or combined with HGF treatment
(Figure 1A, lanes 5 and 6; Additional file 1, lanes 8-9).
Concerning T24-Met3 cells, expression of c-Met was
suppressed 24 h after treatment with Tet (Figure 1B,
lane 2). Together, auto-phosphorylation occurred when
c-Met was over-expressed, and HGF treatment further
enhanced the phosphorylation of c-Met. The results
demonstrate a successful in vitro model in modulating
the expression of c-Met using Tet-off system.
Expression and functional association of c-Met with Axl
and PDGFR-a in vitro
To identify the novel interaction partners of c-Met,
NIH-Met5 cells were first treated with Tet for 24 h,
and then cultured in the absence of Tet for an addi-
tional 4 and 7 days (Figure 2A), respectively. Total
RNA was extracted and subjected to screening using a
cDNA microarray as previously described [35]. Among
192 RTKs, a total of 8 genes were positively correlated
with c-Met over-expression, including Axl, PDGFR-a,
PDGFR-b, ERBB2, ERBB3, MST1R, TIE1 and TIE2
( t a b l e1 ) .O n eo ft h e s ec a n d i d a t eg e n e s - M S T 1 Rw a s
recently reported in our laboratory [6]. In addition, co-
expression of c-Met with Axl and/or PDGFR-a was
also detected in our pilot molecular profiling of RTKs
in human bladder cancer cells in vitro [16]. As a
result, both Axl and PDGFR-a were chosen for subse-
quent analysis. The comparable expression patterns of
c-Met, Axl and PDGFR-a at RNA level were shown in
Figure 2A.
Figure 1 c-Met expression in two stable cell lines in the presence or absence of Tet and/or HGF. The total cell lysate (100 μg) from the
treated cell lines was initially precipitated by the phosphorylated tyrosine antibody (p-Tyr), and then blotted with c-Met antibody to evaluate the
phosphorylation of c-Met. The expression level of c-Met protein was measured by Western blotting. b-actin was used as an internal control. The
intensity of each band in the gel was quantified by densitometry analysis using VisionWorks™ LS image acquisition and analysis software (UVP,
USA) and labeled under each band. A: Both NIH/3T3 and NIH-Met5 cells were treated with or without Tet for 24 h, and then replaced with HGF
(30 ng/ml) for 10 min. B: The stable human bladder cancer cell line T24-Met3 was maintained in the medium in the presence or absence of Tet
for 24 h.
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NIH-Met5 cells. As shown in figure 2B (lane 3), c-Met
was overexpressed in the absence of Tet, while sup-
pressed c-Met expression was demonstrated after treat-
ment of Tet for 24 h, as with that of figure 1. A
reversion of c-Met expression gradually appeared after
removal of Tet for 4 and 7 days. Expression of c-Met
became visible by day 4 and almost completely reversed
by day 7 after removal of Tet (Figure 2B, lanes 4 and 5).
The parental NIH/3T3 cells were used as a control (Fig-
ure 2B, lanes 1 and 2).
Using total c-Met and p-Met as the reference, expres-
sion of Axl and PDGFR-a showed a comparable trend
to that of c-Met at day 4 and day 7 (Figure 2B, lanes 4 -
5), respectively. This positive association of Axl or
PDGFR-a with c-Met expression was also demonstrated
in T24-Met3 human bladder cancer cell line (Figure
1B). However, no difference of Axl and PDGFR-a
expression was detected in NIH3T3 cells (Figure 2B,
lanes 1 and 2). Taken together, expression patterns of
total c-Met and p-Met were positively correlated with
Axl and PDGFR-a expression, suggesting a functional
relationship between Axl/PDGFR-a and c-Met.
Correlation of c-Met expression with Axl and PDGFR-a
status in human bladder cancer cells
Both UB40 and UB47 are two bladder cancer cell lines
established locally from primary bladder cancer of
superficial and muscle-invasive type, respectively [6].
Apparent expression of c-Met and p-Met protein was
detected in these two cell lines, and both Axl and
PDGFR-a also showed a comparable expression pat-
tern (Figure 3A). To confirm their functional interac-
tion, these cell lines were maintained under serum
starvation for 12 h, and then treated with HGF (30
ng/ml) for 10 min (Figure 3A). Up-regulation of Axl
and PDGFR-a was demonstrated in UB40 and UB47
cells after HGF stimulation with a corresponding
increase of p-Met (Figure 3A). Level of p-Met posi-
tively correlated with the expression of Axl and
PDGFR-a, suggesting a relationship among c-Met, Axl
and PDGFR-a.
A
Figure 2 Expression of c-Met, phosphorylated c-Met, Axl and PDGFR-a in NIH/3T3 and NIH-Met5 cells in the presence or absence of
tetracycline. A: A 192 RTK gene cDNA chip was used to screen the gene expression profiles which are positively correlated with c-Met in NIH/
3T3 and inducible NIH-Met5 cell lines. A total of 8 RTK genes were shown to positively correlate with c-Met over-expression by CAST analysis
(Methods). Only the gene expression profiles of c-Met, Axl and PDGFR-a are shown. NIH/3T3 (1D): the parental NIH/3T3 cell without Tet for 24 h;
NIH-Met5 (1D): NIH-Met5 cell without Tet for 24 h; 4D: NIH-Met5 cell with Tet for 24 h followed by Tet-free treatment for another 4 days; 7D:
NIH-Met5 cell with Tet for 24 h followed by Tet-free treatment for another 7 days. Relative expression level of each gene is obtained as
compared with the common reference RNA [47] B: The expression levels of c-Met, p-Met, Axl and PDGFR-a were evaluated in NIH/3T3 and NIH-
Met5 cells without Tet treatment (lanes 1 and 3), or after treatment for 24 h first and then replaced with Tet-free medium for additional 4 and 7
days, (lanes 4 and 5) by Western blotting. b-actin was used as an internal control. The numbers under each band represent the relative intensity.
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PDGFR-a, UB40 cancer cells were transfected with c-
Met, Axl and PDGFR-a specific siRNAs at the optimal
concentrations for 48 h. When expression of each recep-
tor protein was suppressed by their specific siRNA,
expression levels of the other two proteins showed a
trend of down-regulation, with a higher correlation
between c-Met and Axl (Figure 3B). However, co-immu-
noprecipitation assay did not reveal evidence of direct
interaction among these three RTK proteins at cell
membrane level (data not shown). Taken together, the
a b o v ed a t ad e m o n s t r a t eac r o s s - t a l ka m o n gc - M e t ,A x l
and PDGFR-a in a protein-protein interaction indepen-
dent manner in human bladder cancer cells.
The involvement of MEK/ERK signaling pathway in the
transactivation of Axl and PDGFR-a by c-Met
There are several reports of signaling regulation about
RTK transactivation. For example, a HGF-independent
activation of c-Met by fibronectin was reported to pro-
mote the tumor invasion/metastasis [36]. Through bind-
ing to a5b1-integrin, fibronectin directly associates with
c-Met and activates both Src and focal adhesion kinase
activity. To clarify the potential involvement of this c-
Met/Src-related signaling event, the Src inhibitor PP2
(Calbiochem, Merck, Darmstadt, Germany) was used to
treat serum starved UB40 cells for 24 h. As shown in
Figure 4A, suppression of Src phosphorylation did not
alter the levels of c-Met and Axl, indicating that Src is
not involved in the cross-talk of the three RTKs.
It is well known that MEK/ERK 1/2 is one of the most
important transducer proteins when HGF binds to c-Met
[1]. Both FTI-277 (a Ras farnesylation inhibitor; Calbio-
chem, San Diego, CA, USA) and PD98059 (a MEK 1
inhibitor; Cashmere Biotech Co., Taipei, Taiwan) were
used to verify the involvement of MEK/ERK 1/2 signaling
in c-Met-mediated activation of Axl and PDGFR-a.W e
showed that ERK phosphorylation was abrogated by
PD98059 after HGF treatment for 24 h (Figure 4B, lanes
4 and 8) compared to FTI-277 (Figure 4B, lanes 3 and 7),
suggesting the existence of a ras-independent phosphory-
lation of ERK mediated by HGF. The HGF-up-regulated
Axl and PDGFR-a could be inhibited by PD98059 (Fig-
ure 4B, lanes 4 and 8), supporting the involvement of
MEK/ERK 1/2 signaling in this transactivation event. In
summary, MEK/ERK 1/2 signaling is involved in the
transactivation of Axl and PDGFR-a by HGF/c-Met
pathway in human bladder cancer cell lines, but is inde-
pendent of ras or Src activity.
The effect of cross-talk of c-Met, Axl, and PDGFR-a on cell
migration
Upon HGF stimulation, c-Met induces several biological
responses that collectively give rise to a program known
B
Figure 3 Validation of the transactivation of c-Met, Axl and PDGFR-a in human bladder cancer cells. A: Levels of c-Met, p-c-Met, Axl and
PDGFR-a were measured in bladder cancer cell lines UB40 and UB47 by Western blotting after serum starvation for 24 h followed by HGF
treatment for 10 min. B. c-Met, Axl and PDGFR-a protein expression was measured in UB40 cells after transfection with RTK-specific siRNAs (500
nM) by Western blotting. b-actin is a loading control. M: Mock transfection control. S: scramble siRNA (500 nM) is a negative control. The
numbers under each band represent the relative intensity.
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of cross-talk among c-Met, Axl and PDGFR-a, cell
migration assay was conducted. The transwell experi-
ment showed that migration of TSGH8301 bladder can-
cer cells was considerably suppressed by c-Met siRNA
knock-down (p < 0.001). In addition, apparent inhibition
was also demonstrated when shRNA for Axl or PDGFR-
a alone was treated (p < 0.01) (Figure 5A and 5B). Fig-
ure 5C shows that the siRNA for c-Met and shRNAs for
Axl and PDGFR-a,TSGH8301, indeed suppressed their
target gene expression in TSGH8301 cells. This result is
consistent with the reports on Axl in the breast [37]
and liver cancers [38], and on the PDGFR-a in liver
cancer [39], respectively. Our result suggests that c-Met,
Axl and PDGFR-a may induce comparable biological
functions, possibly through the same signaling pathway
or inter-connecting signal network.
Clinical implication of c-Met, Axl, and PDGFR-a co-
expression patterns in human bladder cancer patients
To clarify the clinical implication of the above-men-
tioned findings in vitro, expression levels of c-Met, Axl
and PDGFR-a were examined by immunohistochemis-
try in a total of 65 cases of locally advanced and meta-
static bladder tumors. Co-expression of c-Met/Axl/
PDGFR-a in a case of a bladder cancer tissue was
demonstrated in Figure 6. Collectively, overexpression
of c-Met, Axl, and PDGFR-a was found in 30 (46.2%),
52 (80%), and 40 (61.5%) cases, respectively. Co-
expression of two receptors was revealed in 22 (33.8%,
c-Met/Axl), 27 (41.5%, c-Met/PDGFR-a), and 17
(26.2%, Axl/PDGFR-a) cases. Fourteen cases (21.5%)
showed co-expression of three receptors (c-Met/Axl/
PDGFR-a). In these human bladder tumors, over-
expression of PDGFR-a was correlated with nodal
metastasis and overexpression of c-Met or c-Met/Axl/
PDGFR-a showed the most significant correlation with
poor patient survival (p < 0.01) followed by c-Met/
PDGFR-a,P D G F R - a, c-Met/Axl, and Axl/PDGFR-a (p
< 0.05) (table 2). Kaplan Meier survival analysis
showed that cumulative survival of patients with high
expression of c-Met/Axl and c-Met/PDGFR-a was sig-
nificantly lower than those with lower expression (Log
rank test, p < 0.05) (Figure 7A and 7B). After adjusting
for nodal status, multivariate analysis using log rank
test revealed that indicators associated with poor long
term survival were over-expression of c-Met and co-
expression of c-Met/Axl/PDGFR-a (p =0 . 0 1 5 )( d a t a
not shown). We next used a Cox proportional hazards
models to determine the relative risk (RR) of overall
survival with 95% confidence interval (CI). The RR of
poor long term survival was 3.340 for over-expression
of c-Met, and 3.860 for co-expression of c-Met/Axl/
PDGFR-a. Taken together, our results indicate that, in
Figure 4 The involvement of signaling regulation in the cross-talk of RTKs in human bladder cancer cells. A: The UB40 cells were first
pre-incubated with Src inhibitor (PP2) overnight. Then, phosphorylation status of Src, c-Met and Axl was evaluated after HGF stimulation for
10min. The PP3 (Calbiochem, Merck, Darmstadt, Germany) was used as a negative control for Src inhibition. The numbers under each band
represent the relative intensity. B: After serum-starvation, UB40 and UB47 cells were treated with FTI-277 or PD98059 for 1 h, and then with HGF
for 24 h. The p-ERK and levels of Ras, ERK, Axl and PDGFR-a expression were measured using specific antibodies by Western blotting. b-actin
was used as an internal control. M: Mock transfection control.
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tive role in the progression of human bladder cancer.
Discussion and conclusions
In this study, we showed that both Axl and PDGFR-a
have a functional interaction with c-Met in vitro and in
vivo. This is the first report showing their potential clin-
ical importance in human bladder cancer. The results
concur with co-expression of c-Met/PDGFR-a in all of
9 human bladder cancer cell lines reported by Black and
his colleagues [40]. The interaction between c-Met and
Axl or PDGFR-a was further corroborated by HGF sti-
mulation and siRNA silencing experiments in vitro.T h e
interaction among these three RTKs may be initiated by
protein-protein interaction or signaling transduction.
The former possibility was excluded by co-immunopre-
cipitation assay (data not shown). In terms of signal reg-
ulation, the successful inhibition of c-Met activation by
PD98059, but not by FTI-277 (ras inhibitor) or PP2 (Src
inhibitor), suggests a ras- and Src-independent MEK/
ERK 1/2 signaling in the transactivation of Axl and
PDGFR-a. Our results seem to imply the existence of a
novel mechanism by which c-Met transactivates the
expression of Axl and PDGFR-a. Additional experi-
ments are required to clarify whether protein kinase C
is involved in this cross-talk in vivo.
Further support for our hypothesis of regulation at
transcriptional level comes from several prior reports.
The Sp1/Sp3 cis-acting elements were demonstrated to
activate the promoter of Axl in various cancer cell lines
[41]. Moreover, Sp1 response elements are detected in
PDGFR-a promoter region [42,43]. Given that c-Met
induces the phosphorylation of Sp1 and enhances down-
stream gene expression through MEK/ERK signaling
pathway [44,45], c-Met might up-regulate the expression
of Axl and PDGFR-a through Sp1. The dose-dependent
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Figure 5 The effect of c-Met, Axl and PDGFR-a expression on the migration of bladder cancer cells. (A) TSGH8301 bladder cancer cells (2
× 105 cells/200 μl DMEM) were plated in the upper chamber in the presence of 500 nM siRNA for c-Met, Axl and PDGFR-a, respectively, and
analyzed for cell migration at 36 h. The filter was stained with 2% crystal violet, and the cells migrated to the opposite side of the filter were
counted. (B) Quantification of (A). Data represents mean ± SD of three experiments. * *: p < 0.01, * * *: p < 0.001, by Student’s t test. (C) The
inhibitory effect of siRNA on c-Met, Axl and PDGFR-a expression was analyzed by Western blot analysis. Expression of c-Met, Axl and PDGFR-a
was suppressed only in those cells transfected with c-Met, Axl or PDGFR-a siRNA/shRNA. There was no reduction of c-Met, Axl or PDGFR-a
proteins in cells transfected with scrambled siRNA/shRNA. Ctrl: control treatment; S: scramble siRNA.
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supports our speculation (Additional file 2).
It has been reported that HGF is expressed in fibro-
blast-like cells, smooth muscle cells, and endothelial
cells of the bladder [46]. Expression of c-Met on the
cancer cell surface thus may enable the paracrine activa-
tion in vivo, irrespective of their capability to synthesize
HGF. The correlation of co-expression of two or three
of the RTKs with patient survival supports the “invasive
growth” program in carcinomas with multiple RTK
over-expression [13,15,47]. The prognostic significance
of c-Met, whether alone or co-expressed with Axl/
PDGFR-a, supports the clinical relevance of c-Met-
directed therapy (e.g. PHA665752) for human bladder
cancer. Since the importance of co-targeting therapy for
human bladder cancer having co-expressed RTKs has
been demonstrated [15,47], a prospective study is
PDGFR
AXL
c-Met
Figure 6 Co-expression of c-Met, Axl and PDGFR-a in a human bladder cancer specimen. Representative results of co-expression of c-Met,
Axl and PDGFR-a in three serial sections of a human bladder cancer specimen. The three sections were incubated with anti-c-Met, anti-Axl or
anti-PDGFR-a antibody, respectively (200X). The arrow indicates the specific expression of receptor protein around the membrane of the cancer
cells.
Table 2 Correlation of c-Met, Axl, and PDGFR-a protein
expression with clinicopathologic parameters of patients
with locally advanced and metastatic bladder cancers
Expression pattern Grade T
status*
Multiple Node
(+)
Survival
c-Met 0.561 0.904 0.727 0.321 0.009
†
Axl 0.409 0.105 0.795 0.300 0.789
PDGFR-a 0.344 0.470 0.718 0.049
† 0.027
†
c-Met & Axl 0.140 0.070 0.277 0.061 0.031
†
c-Met & PDGFR-a 0.184 0.686 0.957 0.802 0.011
†
Axl & PDGFR-a 0.439 0.585 0.762 0.369 0.049
†
c-Met & Axl & PDGFR-
a
0.595 0.377 0.346 0.281 0.008
†
*Statistical analysis was performed between stage pT2 (21), pT3 (27) and
stage pT4 (17), according to TNM (2002) classification criteria.
† p value less than 0.05.
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PDGFR-a as an additional biomarker or implementation
of MEK1/2 inhibitor in the design of c-Met-targeting
therapy for human bladder cancer patients.
It is interesting to note that induction of Axl via
‘’kinase switching’’ confers the Gleevec resistance in
relapsed patients with c-Kit- or PDGFR-a-driven tumors
of the gastrointestinal tract [48]. Therefore, evaluation of
RTK expression profile in human cancer may provide
signaling network information and help in prediction of
potential drug resistance [49]. Olaussen et al. showed
that combinations of tyrosine kinase inhibitors could
induce a synergistic antitumor effect and thus improve
the therapeutic efficacy [50]. When more highly selective
or multi-target tyrosin kinase inhibitors become avail-
able, the discovery of co-expression of RTKs in cancer
cells highlights the necessity for individualized therapies
in the future.
Additional material
Additional file 1: c-Met expression in NIH/3T3 and NIH-Met5 cell
lines in the presence or absence of Tet and/or HGF. The cells and
the treatment is the same as Figure 1A, except the expression of IgG
was shown as the loading control. M: protein marker.
Additional file 2: The relationship among c-Met, Sp1, Axl and
PDGFR-a demonstrated by c-Met siRNA. NIH-Met5 cells (1 × 10
6/plate)
were transfected with c-Met siRNA (250 nM and 500 nM) for 24 h. Then,
cells were harvested and total protein was extracted and analyzed for c-
Met, Sp1, Axl and PDGFR-a expression by Western blotting. b-actin was
used as the internal control. The numbers under each band represent
the relative intensity.
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Figure 7 Prognostic significance of co-expression of c-Met and Axl or PDGFR-a in human bladder cancer patients. Kaplan-Meier survival
analysis revealed that co-expression of c-Met/Axl (A) or c-Met/PDGFR-a (B) is significantly associated with poor survival in bladder cancer
patients than those with single-receptor-positive or no receptor expression (p = 0.021 & 0.049, respectively).
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